Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss solutions. Reporting on Feb. 6, Eli Lilly is expected to post quarterly earnings of $2.76 per share, up 32.1% from the same period a year ago. Revenue for the quarter is expected to climb 21.4% to $8.86 billion, according to Zacks consensus estimates. On Wednesday, Eli Lilly’s chief rival in the weight-los…